EDMONTON, June 12 /CNW/ - CardioMetabolics(TM) inc., today announced that
Kimmo Lucas, President and CEO, will present at the Business Forum at the 2008
BIO International Convention in San Diego, California.
WHEN: Tuesday, June 17th at 2:30 pm (PDT)
WHERE: San Diego Convention Center, San Diego
About CardioMetabolics(TM) inc.
Edmonton-based CardioMetabolics Inc. is a privately held, late-stage,
biopharmaceutical company focused on commercializing drug product candidates
in the novel class of energy metabolism agents, referred to as PDK blockers.
CardioMetabolics' technology is focused on metabolic modulation, through the
use of dichloroacetate (DCA) and related compounds, which improve energy
production by favoring glucose metabolism. "DCA i.v." is the late stage anchor
product in the PDK Blocker platform which includes earlier stage compounds
that target the treatment of chronic conditions, including cardiovascular
disease and related metabolic conditions (e.g., diabetes). Cardiovascular
disease is the "number one" cause of death in North America, and each year in
the United States alone, over 650,000 open heart surgeries are conducted.
CardioMetabolics(TM) inc. was recognized as "Emerging Company of the Year" at
BioAlberta's 8th Annual AGM and Awards Gala.
About the 2008 BIO International Convention
The Biotechnology Industry Organization hosts the 2008 BIO International
Convention which will feature keynote presentations from industry and global
leaders as well as business partnering meetings. The convention includes more
than 200,000 square feet of exhibitions showcasing the latest advancements in
biotechnology alongside an array of potential partners, service providers and
international delegations. For more information visit http://www.bio2008.org/.
This news release may contain forward-looking statements, including
statements regarding the business and anticipated financial performance of
CardioMetabolics inc. Forward looking statements involve risks and
uncertainties related to our business and the general economic environment,
many beyond our control. These risks, uncertainties and other factors could
cause our actual results to be materially different. Some of the factors that
could cause such differences include exchange rate fluctuations, market demand
for our products and services, the general state of the economy, our ability
to execute projects and deliver solutions, our ability to retain and attract
qualified employees and contain payroll expenses, the availability of credit
lines and future financing, legal claims, the results of our scientific
research, in particular the results of clinical trials, our ability to obtain
necessary regulatory approvals to continue or initiate further or future
clinical trials, and other factors.
For further information:
For further information: CardioMetabolics Inc., Debbra DeMarco, Director
of Investor Relations, Phone: (780) 438-2818, ext 223, Fax: (780) 438-2874,
E-mail: firstname.lastname@example.org, Internet:
http://primalfx.com/cardio; Investor Relations, Ross Marshall, The Equicom
Group Inc., Phone: (416) 815-0700 (Ext. 238), Fax: (416) 815-0080, E-mail: